Skip to main content

Breogan Rodriguez Acevedo

Institutions of which they are part

Senior researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Breogan Rodriguez Acevedo

Institutions of which they are part

Senior researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Search of immune signatures associated with multiple sclerosis disease phenotypes

IP: Nicolás Miguel Fissolo
Collaborators: Luciana Midaglia Fernandez, Breogan Rodriguez Acevedo
Funding agency: Instituto de Salud Carlos III
Funding: 169400
Reference: PI20/00276
Duration: 01/01/2021 - 30/06/2025

Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC)

IP: Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC)
Collaborators: Susana Otero Romero, Carlos Nos Llopis, Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC), José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Margarida Capell Maymo, Carmen Tur Gomez, Jordi Barquinero Mañez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Neuroimmunologia Clínica. Centre d'Esclerosi Múltiple de Catalunya (CEMCAT( (GRC), M Jesus Arevalo Navines, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Silvia Casacuberta Serra, Sergio Vergara Ruiz, Luciana Midaglia Fernandez, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Mireia Castillo Juarez, Nicolás Miguel Fissolo , Georgina Arrambide García
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50000
Reference: 2014 SGR 1082
Duration: 01/01/2014 - 31/12/2016

Related news

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

Related professionals

Hanaa Boudoukhan Benriyyan

Hanaa Boudoukhan Benriyyan

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Ana Torcida Alonso

Ana Torcida Alonso

Research technician
Stroke research
Read more
Lluria Cornellas Escayola

Lluria Cornellas Escayola

Main researcher
Molecular Imaging and Therapy
Read more
Victoria Carla Fernández Rodríguez

Victoria Carla Fernández Rodríguez

Predoctoral researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.